Exercise-induced High-sensitivity Troponin Levels as a Predictor for Obstructive Coronary Artery Disease (EUROCAD)
- To compare hs-TnT levels after a cardiac stress test in patients with vs. patients without CAD
- To assess the level of post-exercise hs-TnT predicting CAD (using ROC-analysis)
- To determine the sensitivity, specificity and accuracy of this exercise-induced hsTopT level in predicting CAD, either alone or in relation to traditional patient-related and exercise test-related metrics
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Dries De Cock, MD
- Phone Number: 003216341519
- Email: dries.decock@uzleuven.be
Study Contact Backup
- Name: Nick Hiltrop, MD
- Phone Number: 003216344235
- Email: nick.hiltrop@uzleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- UZLeuven
-
Contact:
- Dries De Cock, MD
- Phone Number: 003216341519
- Email: dries.decock@uzleuven.be
-
Contact:
- Marina Claes, bachelor nurse
- Phone Number: 003216342461
- Email: marina.claes@uzleuven.be
-
Principal Investigator:
- Walter Desmet, MD, PhD
-
Sub-Investigator:
- Christophe Dubois, MD, PhD
-
Sub-Investigator:
- Tom Adriaenssens, MD, PhD
-
Sub-Investigator:
- Peter Sinnaeve, MD, PhD
-
Sub-Investigator:
- Johan R Bennett, MD
-
Sub-Investigator:
- Dries De Cock, MD
-
Sub-Investigator:
- Nick Hiltrop, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with suspected CAD, planned for diagnostic coronary angiogram
- Patients with previous revascularization, suspected of recurrent ischemia
Exclusion Criteria:
- Congestive cardiomyopathy with LV EF < 35%
- Renal failure with eGFR < 30 ml/min
- Known structural or severe valvular heart disease
- Prior CABG
- Previous ACS < 6 weeks
- Known incomplete revascularization after previous PCI
- Unstable angina or ACS (defined as unstable anginal symptoms + ECG changes or hs-TnT > 0.053 ng/L)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
patients with hemodynamic significant CAD;
|
|
patients without hemodynamic significant CAD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Presence of coronary artery stenosis more than 50%
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UZL9281
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.